angioplasty

EuroPCR 2021 | CELEBRATE-02: Nuevo inhibidor de la glicoproteína IIb IIIa para infartos con ST

EuroPCR 2021 | CELEBRATE-02: Novel Glycoprotein IIb/IIIa Inhibitor for ST-Segment Elevation Infarction

Promising fast subcutaneous administration and a quick and potent antiplatelet effect, here comes a novel glycoprotein IIb/IIa inhibitor called RUC-4. This novel drug was tested in the CELEBRATE-02 study, presented at EuroPCR 2021 and simultaneously published in EuroIntervention. The mean platelet inhibition begins 15&nbsp;minutes after injection and increases with each of the three tested doses<a href="https://solaci.org/en/2021/05/26/europcr-2021-celebrate-02-novel-glycoprotein-iib-iiia-inhibitor-for-st-segment-elevation-infarction/" title="Read more" >...</a>

Balancear el riesgo de sangrado vs trombótico para definir el tiempo de doble antiagregación

Very Short Dual Antiplatelet Therapy after Complex PCI

The 1-month outcomes of dual antiplatelet therapy (DAPT) followed by clopidogrel monotherapy were comparable to 12-month DAPT in patients with both simple and complex PCI. There was no significant interaction between DAPT period and procedure difficulty.&nbsp; This is a post hoc study of the STOPDAPT-2 that looked at the complex PCI patient subgroup.&nbsp;&nbsp; It is<a href="https://solaci.org/en/2021/05/24/very-short-dual-antiplatelet-therapy-after-complex-pci/" title="Read more" >...</a>

SAFE-PAD: Dispositivos liberadores de paclitaxel en enfermedad periférica

ACC 2021 | SAFE-PAD: Paclitaxel-Eluting Devices in Peripheral Disease

This work was conducted alongside the US Food and Drug Administration (FDA) to investigate the association between all-cause mortality and paclitaxel-eluting devices in peripheral vascular disease. According to data from SAFE-PAD, presented at the American College of Cardiology (ACC) 2021 Congress and simultaneously published in JAMA, there is no increase in mortality compared with conventional<a href="https://solaci.org/en/2021/05/19/acc-2021-safe-pad-paclitaxel-eluting-devices-in-peripheral-disease/" title="Read more" >...</a>

ACC 2021 | El estrés aumentó en los eventos en pacientes jóvenes con IAM previo

ACC 2021 | Stress Increases Events in Young Patients with Prior MI

Young or middle-aged patients who have already suffered a heart attack have almost twice as many adverse events when they continue to be under emotional stress after the initial suffering. The association between psychological factors and events is attenuated after making adjustments that include markers of inflammation such as interleukin-6. It follows that inflammation plays<a href="https://solaci.org/en/2021/05/18/acc-2021-stress-increases-events-in-young-patients-with-prior-mi/" title="Read more" >...</a>

Estenosis-aórtica-severa2-compressor

Is Rheumatic Etiology Counter Indicated for TAVR?

Patients with rheumatic aortic stenosis have been systematically excluded from all studies on transcatheter aortic valve replacement (TAVR).&nbsp; This study compared TAVR vs surgical aortic valve replacement (SAVR) outcomes in patients with rheumatic aortic stenosis and also vs TAVR outcomes in patients with degenerative aortic stenosis.&nbsp; The study looked at rheumatic aortic stenosis patients receiving<a href="https://solaci.org/en/2021/05/17/is-rheumatic-etiology-counter-indicated-for-tavr/" title="Read more" >...</a>

El aumento de la experiencia de los operadores mejora los resultados en el TAVI

ST-Segment Elevation Infarction After TAVR: Problems in Every Aspect

For interventional cardiologists, treating an ST-segment elevation infarction in a patient with transcatheter aortic valve replacement (TAVR) is challenging in many ways. Longer door-to-balloon times and higher rates of primary angioplasty failure than in the general population are translated into very high short- and mid-term mortality. This multicenter study, recently published in JACC, included 118&nbsp;patients<a href="https://solaci.org/en/2021/05/10/st-segment-elevation-infarction-after-tavr-problems-in-every-aspect/" title="Read more" >...</a>

Xience Receives CE Mark for Short and Ultrashort DAPT Schemes

Dual antiplatelet therapy (DAPT) one month after angioplasty with Xience stent was approved in Europe for patients with high risk of bleeding. &nbsp; The CE Mark approval comes after studies Xience&nbsp;28 and Xience&nbsp;90 are published. Immediately after authorization, Abbot was fast to announce what they consider to be the shortest approved scheme with the most<a href="https://solaci.org/en/2021/04/26/xience-receives-ce-mark-for-short-and-ultrashort-dapt-schemes/" title="Read more" >...</a>

Impacto del FFR post stent ¿dato útil o solo una curiosidad?

Impact of FFR After Stenting: Useful or Mere Fun Fact?

Suboptimal fractional flow reserve (FFR) results after stenting only have a moderate impact on clinical hard points but might predict a much higher risk of reintervention. FFR has shown a huge impact on the decision-making process when it comes to revascularizing (or not) a lesion. Its impact after angioplasty has not been fully studied, particularly<a href="https://solaci.org/en/2021/04/12/impact-of-ffr-after-stenting-useful-or-mere-fun-fact/" title="Read more" >...</a>

Lower Mortality with Rechanneling vs. Medical Therapy

We had to wait for it, but we have finally seen a benefit in hard endpoints—such as mortality—derived from rechanneling. Patients with chronic total occlusion (CTO) in whom rechanneling was used as initial strategy showed higher survival rated compared with those receiving medical therapy. As initial treatment strategy, rechanneling a CTO did not show any<a href="https://solaci.org/en/2021/04/07/lower-mortality-with-rechanneling-vs-medical-therapy/" title="Read more" >...</a>

SOLACI PERIPHERAL | Common, superficial and deep femoral artery recanalization

SOLACI PERIPHERAL | 6th Clinical Case: Common, Superficial and Deep Femoral Artery Recanalization

Here is a new SOLACI PERIPHERAL Case! In this opportunity, Dr. Ana Paula Mollón (Arg.) presents “Common, Superficial and Deep Femoral Artery Recanalization”. This is the 6th clinical case presented by SOLACI Peripheral. The purpose of this space is to encourage and further the exchange of experiences and opinions, to keep advancing our knowledge in<a href="https://solaci.org/en/2021/04/06/solaci-peripheral-6th-clinical-case-common-superficial-and-deep-femoral-artery-recanalization/" title="Read more" >...</a>

Top